Dupixent Positive Phase 3 Data in Children One to 11 Years of Age With Eosinophilic Esophagitis Published in NEJM
June 27, 2024
June 27, 2024
PARIS, France, June 27 (TNSres) -- Sanofi, a life sciences company, issued the following news release:
* * *
* Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one year
* Dupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group
* * *
The New England Journal of Medicine has publ . . .
* * *
* Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one year
* Dupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group
* * *
The New England Journal of Medicine has publ . . .